Indofarma Tbk PT banner

Indofarma Tbk PT
IDX:INAF

Watchlist Manager
Indofarma Tbk PT Logo
Indofarma Tbk PT
IDX:INAF
Watchlist
Price: 126 IDR Market Closed
Market Cap: Rp390.5B

Relative Value

The Relative Value of one INAF stock under the Base Case scenario is hidden IDR. Compared to the current market price of 126 IDR, Indofarma Tbk PT is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INAF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

INAF Competitors Multiples
Indofarma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Indofarma Tbk PT
IDX:INAF
390.5B IDR 1.9 -1.3 -2.9 -2.9
US
Eli Lilly and Co
NYSE:LLY
856.7B USD 13.1 41.5 28 29.9
US
Johnson & Johnson
NYSE:JNJ
566.8B USD 6 21.1 14.7 18.1
CH
Roche Holding AG
SIX:ROG
243.3B CHF 4 18.9 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 4.9 28.3 15.7 22.2
US
Merck & Co Inc
NYSE:MRK
282.6B USD 4.3 15.5 9.6 11.7
CH
Novartis AG
SIX:NOVN
222.2B CHF 5.1 20.5 12.7 16.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.7 9
US
Pfizer Inc
NYSE:PFE
153.4B USD 2.5 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD 2.4 16.4 7 8.6
P/E Multiple
Earnings Growth PEG
ID
Indofarma Tbk PT
IDX:INAF
Average P/E: 21.4
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.9
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Indofarma Tbk PT
IDX:INAF
Average EV/EBITDA: 49
Negative Multiple: -2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.7
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.6
3%
3.2
CH
Novartis AG
SIX:NOVN
12.7
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
1%
7.7
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Indofarma Tbk PT
IDX:INAF
Average EV/EBIT: 108
Negative Multiple: -2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.9
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.1
6%
3
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
22.2
21%
1.1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
CH
Novartis AG
SIX:NOVN
16.3
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.6
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett